Expression of C-X-C chemokine receptor types 1/2 in patients with gastric carcinoma: Clinicopathological correlations and significance

Oncology Letters

Volumn 5, Issue 2, 2013, Pages 574-582

  Wang, Jun Pu ^a   Hu, Wan Ming ^a   Wang, Kuan Song ^a   Yu, Jun ^a   Luo, Bai Hua ^a   Wu, Chang ^a   Chen, Zhi Hong ^a   Luo, Geng Qiu ^a   Liu, Yu Wu ^a   Liu, Qin Lai ^a   Xiao, Yan ^a   Zhou, Hai Yan ^a   Yang, Xiao Jing ^a   Jiang, Hai Ying ^a   Li, Jing He ^a   Wen, Ji Fang ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

C X C chemokine receptor types 1 2; Chemokine; Gastric carcinoma; Tumor

Indexed keywords

CD34 ANTIGEN; CHEMOKINE RECEPTOR CXCR1; CHEMOKINE RECEPTOR CXCR2; CYCLIN D1; EPIDERMAL GROWTH FACTOR RECEPTOR; GELATINASE A; GELATINASE B; KI 67 ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; TISSUE INHIBITOR OF METALLOPROTEINASE 2; UVOMORULIN; VASCULOTROPIN;

ADULT; AGED; ANGIOGENESIS; APOPTOSIS; ARTICLE; CANCER INVASION; CANCER STAGING; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; GASTRECTOMY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RISK FACTOR; STOMACH CARCINOMA; TUMOR GROWTH;

EID: 84871590244     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.1043     Document Type: Article

References (50)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and ParkinDM: GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. Lyon, France: International Agency for Research on Cancer; 2010. http://globocan.iarc.fr, accessed on February 27, 2012.
2. Alberts SR, Cervantes A and van de Velde CJ: Gastric cancer: epidemiology, pathology and treatment. Ann Oncol 14 (Suppl 2): ii31-36, 2003.
3. Yang L: Incidence and mortality of gastric cancer in China. World J Gastroenterol 12: 17-20, 2006.
4. Hyung WJ, Noh SH, Yoo CH, et al: Prognostic significance of metastatic lymph node ratio in T3 gastric cancer. World J Surg 26: 323-329, 2002.
5. Balkwill F and Mantovani A: Inflammation and cancer: back to Virchow? Lancet 357: 539-545, 2001.
6. Nathan C and Ding A: Nonresolving inflammation. Cell 140: 871-882, 2010.
7. Mantovani A: Cancer: Inflaming metastasis. Nature 457: 36-37, 2009.
8. Righi E, Kashiwagi S, Yuan J, et al: CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer. Cancer Res 71: 5522-5534, 2011.
9. Wendel C, Hemping-Bovenkerk A, Krasnyanska J, et al: CXCR4/CXCL12 participate in extravasation of metastasizing breast cancer cells within the liver in a rat model. PLoS One 7: e30046, 2012.
10. Balkwill FR: The chemokine system and cancer. J Pathol 226: 148-157, 2012.
11. Lazennec G and Richmond A: Chemokines and chemokine receptors: new insights into cancer-related inflammation. Trends Mol Med 16: 133-144, 2010.
12. Murphy PM: The molecular biology of leukocyte chemoattractant receptors. Annu Rev Immunol 12: 593-633, 1994.
13. Kelvin DJ, Michiel DF, Johnston JA, et al: Chemokines and serpentines: the molecular biology of chemokine receptors. J Leukoc Biol 54: 604-612, 1993.
14. Waugh DJ and Wilson C: The interleukin-8 pathway in cancer. Clin Cancer Res 14: 6735-6741, 2008.
15. Zhang Y, Wang L, Zhang M, Jin M, Bai C and Wang X: Potential mechanism of interleukin-8 production from lung cancer cells: an involvement of EGF-EGFR-PI3K-Akt-Erk pathway. J Cell Physiol 227: 35-43, 2012.
16. Ginestier C, Liu S, Diebel ME, et al: CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest 120: 485-497, 2010.
17. Singh S, Nannuru KC, Sadanandam A, Varney ML and SinghRK: CXCR1 and CXCR2 enhances human melanoma tumourigenesis, growth and invasion. Br J Cancer 100: 1638-1646, 2009.
18. Varney ML, Singh S, Li A, Mayer-Ezell R, Bond R and SinghRK: Small molecule antagonists for CXCR2 and CXCR1 inhibit human colon cancer liver metastases. Cancer Lett 300: 180-188, 2011.
19. Matsuo Y, Raimondo M, Woodward TA, et al: CXC-chemokine/CXCR2 biological axis promotes angiogenesis in vitro and in vivo in pancreatic cancer. Int J Cancer 125: 1027-1037, 2009.
20. Eck M, Schmausser B, Scheller K, Brändlein S and Müller-Hermelink HK: Pleiotropic effects of CXC chemokines in gastric carcinoma: differences in CXCL8 and CXCL1 expression between diffuse and intestinal types of gastric carcinoma. Clin Exp Immunol 134: 508-515, 2003.
21. Wang JP, Hu WM, Wang KS, et al: Upregulation of C-X-C chemokine receptor type 1 expression is associated with late-stage gastric adenocarcinoma. Exp Ther Med 4: 55-60, 2012.
22. Washington K: 7th edition of the AJCC cancer staging manual: stomach. Ann Surg Oncol 17: 3077-3079, 2010.
23. Allred DC, Harvey JM, Berardo M and Clark GM: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11: 155-168, 1998.
24. Harvey JM, Clark GM, Osborne CK and Allred DC: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 17: 1474-1481, 1999.
25. Raman D, Baugher PJ, Thu YM and Richmond A: Role of chemokines in tumor growth. Cancer Lett 256: 137-165, 2007.
26. Ali S and Lazennec G: Chemokines: novel targets for breast cancer metastasis. Cancer Metastasis Rev 26: 401-420, 2007.
27. Vindrieux D, Escobar P and Lazennec G: Emerging roles of chemokines in prostate cancer. Endocr Relat Cancer 16: 663-673, 2009.
28. Orimo A, Gupta PB, Sgroi DC, et al: Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121: 335-348, 2005.
29. Colmone A, Amorim M, Pontier AL, Wang S, Jablonski E and Sipkins DA: Leukemic cells create bone marrow niches that disrupt the behavior of normal hematopoietic progenitor cells. Science 322: 1861-1865, 2008.
30. Singh S, Varney M and Singh RK: Host CXCR2-dependent regulation of melanoma growth, angiogenesis, and experimental lung metastasis. Cancer Res 69: 411-415, 2009.
31. Kitamura T, Kometani K, Hashida H, et al: SMAD4-deficient intestinal tumors recruit CCR1+ myeloid cells that promote invasion. Nat Genet 39: 467-475, 2007.
32. Buonamici S, Trimarchi T, Ruocco MG, et al: CCR7 signalling as an essential regulator of CNS infiltration in T-cell leukaemia. Nature 459: 1000-1004, 2009.
33. Maxwell PJ, Gallagher R, Seaton A, et al: HIF-1 and NF-kappa B-mediated upregulation of CXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells. Oncogene 26: 7333-7345, 2007.
34. Varney ML, Li A, Dave BJ, Bucana CD, Johansson SL and SinghRK: Expression of CXCR1 and CXCR2 receptors in malignant melanoma with different metastatic potential and their role in interleukin-8 (CXCL-8)-mediated modulation of metastatic phenotype. Clin Exp Metastasis 20: 723-731, 2003.
35. Varney ML, Johansson SL and Singh RK: Distinct expression of CXCL8 and its receptors CXCR1 and CXCR2 and their association with vessel density and aggressiveness in malignant melanoma. Am J Clin Pathol 125: 209-216, 2006.
36. Murphy C, McGurk M, Pettigrew J, et al: Nonapical and cytoplasmic expression of interleukin-8, CXCR1, and CXCR2 correlates with cell proliferation and microvessel density in prostate cancer. Clin Cancer Res 11: 4117-4127, 2005.
37. Müller A, Homey B, Soto H, et al: Involvement of chemokine receptors in breast cancer metastasis. Nature 410: 50-56, 2001.
38. Tanaka T, Bai Z, Srinoulprasert Y, Yang BG, Hayasaka H and Miyasaka M: Chemokines in tumor progression and metastasis. Cancer Sci 96: 317-322, 2005.
39. Koizumi K, Hojo S, Akashi T, Yasumoto K and Saiki I: Chemokine receptors in cancer metastasis and cancer cell-derived chemokines in host immune response. Cancer Sci 98: 1652-1658, 2007.
40. Balakin KV, Ivanenkov YA, Tkachenko SE, Kiselyov AS and Ivachtchenko AV: Regulators of chemokine receptor activity as promising anticancer therapeutics. Curr Cancer Drug Targets 8: 299-340, 2008.
41. Ruffini PA, Morandi P, Cabioglu N, Altundag K and CristofanilliM: Manipulating the chemokine-chemokine receptor network to treat cancer. Cancer 109: 2392-2404, 2007.
42. Kakinuma T and Hwang ST: Chemokines, chemokine receptors, and cancer metastasis. J Leukoc Biol 79: 639-651, 2006.
43. Gabellini C, Trisciuoglio D, Desideri M, et al: Functional activity of CXCL8 receptors, CXCR1 and CXCR2, on human malignant melanoma progression. Eur J Cancer 45: 2618-2627, 2009.
44. Roomi MW, Monterrey JC, Kalinovsky T, Rath M and Niedzwiecki A: Comparative effects of EGCG, green tea and a nutrient mixture on the patterns of MMP-2 and MMP-9 expression in cancer cell lines. Oncol Rep 24: 747-757, 2010.
45. Roomi MW, Monterrey JC, Kalinovsky T, Rath M and Niedzwiecki A: Patterns of MMP-2 and MMP-9 expression in human cancer cell lines. Oncol Rep 21: 1323-1333, 2009.
46. Knall C, Worthen GS and Johnson GL: Interleukin 8-stimulated phosphatidylinositol-3-kinase activity regulates the migration of human neutrophils independent of extracellular signal-regulated kinase and p38 mitogen-activated protein kinases. Proc Natl Acad Sci USA 94: 3052-3057, 1997.
47. Cheng GZ, Park S, Shu S, et al: Advances of AKT pathway in human oncogenesis and as a target for anti-cancer drug discovery. Current Cancer Drug Targets 8: 2-6, 2008.
48. MacManus CF, Pettigrew J, Seaton A, et al: Interleukin-8 signaling promotes translational regulation of cyclin D in androgen-independent prostate cancer cells. Mol Cancer Res 5: 737-748, 2007.
49. Venkatakrishnan G, Salgia R and Groopman JE: Chemokine receptors CXCR-1/2 activate mitogen-activated protein kinase via the epidermal growth factor receptor in ovarian cancer cells. J Biol Chem 275: 6868-6875, 2000.
50. Luppi F, Longo AM, de Boer WI, Rabe KF and Hiemstra PS: Interleukin-8 stimulates cell proliferation in non-small cell lung cancer through epidermal growth factor receptor transactivation. Lung Cancer 56: 25-33, 2007.